Study PROCLAIM-CX-2029 and PROCLAIM-CX-072 - Nicholas J. Vogelzang MD Comprehensive Cancer Centers of Nevada @CCCNevada

Study PROCLAIM-CX-2029 and PROCLAIM-CX-072 - Nicholas J. Vogelzang MD Comprehensive Cancer Centers of Nevada @CCCNevada

User Photo
Cancer-News

1 month
18 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Nicholas J. Vogelzang, MD Comprehensive Cancer Centers of Nevada discusses CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced prostate cancer and PROCLAIM-CX-072: Analysis of patients with prostate advanced solid tumors receiving long-term treatment with CX-072, a PD-L1 probody therapeutic, as a single agent or in combination with ipilimumab
Up Next Autoplay